* Organic momentum improved in all segments * A recovery in Swedish housing could drive 18% EBITA gr...
* Increasing activity in the letting market * Net financials miss in Q3 drives negative revisions * ...
Redeye gives an initial comment on the Leqembi royalty for Q3, which came in a bit lower than we exp...
Redeye reviews SynAct Pharma's Q3 report. The ADVANCE study is progressing and on track to enrol all...
Redeye provides a research update following the Q3 report published by OncoZenge earlier today.
Elon AB säger upp kedjeavtalet med sin största handlarkedja, Kökscentrum Södra AB och Belab Elbutik ...
Lipum has presented new topline data from collaborative studies with Linköping University that stren...
Despite the profit warning released ahead of the Q3 report, there were also positives in the report ...
Solteq’s Q3 results were disappointing. Despite the weak quarter, guidance was reiterated, indicatin...
Oriola posted good figures in Q3. Net sales growth was nearly in the double-digits, while the adj.
Redeye comments on CTEK’s Q3 report, which showed weaker growth than expected, but this was compensa...
Redeye provides its initial take on Hansa Biopharma’s Q3 report.
Suominen had published some details of its Q3 earnings before the actual release in connection with ...
Redeye reviews BioInvent's Q3 report 2025. The company is doubling down on BI-1206 and BI-1808.
Suominen's Q3 headline figures had been pre-announced in conjunction with the profit warning on 15 O...
